Other Events ·
Acumen pays off $23.3M debt and cuts 90% of staff in $7.75M restructuring
ABOSAcumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals voluntarily prepaid approximately $23.3 million to fully satisfy its obligations under a term loan agreement with K2 HealthVentures, releasing all associated liens and conversion rights. Concurrently, the company announced it is ceasing development of sabirnetug and initiating a workforce reduction affecting 52 employees, representing roughly 90% of its staff. This restructuring is expected to incur approximately $7.75 million in severance costs, with completion targeted for early 2027 as the firm evaluates strategic options for its Enhanced Brain Delivery program. Acumen Pharmaceuticals operates in the biotechnology sector, focusing on drug discovery and development.